Portal de Periódicos da CAPES

Treatment of children with chronic hepatitis C with recombinant interferon-α: A pilot study

1992; Lippincott Williams & Wilkins; Volume: 16; Issue: 4 Linguagem: Inglês

10.1002/hep.1840160405

1527-3350

M Ruíz-Moreno, Maria José Rua, Inmaculada Castillo, Maria Dolores García-Novo, Maravillas Santos, Sonia Navas, Vicente Carréño,

Monoclonal and Polyclonal Antibodies Research

HepatologyVolume 16, Issue 4 p. 882-885 Original ArticleFree Access Treatment of children with chronic hepatitis C with recombinant interferon-α: A pilot study Mercedes Ruiz-Moreno, Mercedes Ruiz-Moreno Department of Pediatrics, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorMaria José Rua, Maria José Rua Department of Pediatrics, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorInmaculada Castillo, Inmaculada Castillo Department of Gastroenterology, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorMaria Dolores García-Novo, Maria Dolores García-Novo Department of Gastroenterology, Hospital Niño Jesús, 28009 Madrid, SpainSearch for more papers by this authorMaravillas Santos, Maravillas Santos Department of Pediatrics, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorSonia Navas, Sonia Navas Department of Gastroenterology, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorDr. Vicente Carreño, Corresponding Author Dr. Vicente Carreño Department of Gastroenterology, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridHepatology Unit, Department of Gastroenterology, Fundación Jiménez Díaz, Avda. Reyes católicos 2, 28040 Madrid, Spain===Search for more papers by this author Mercedes Ruiz-Moreno, Mercedes Ruiz-Moreno Department of Pediatrics, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorMaria José Rua, Maria José Rua Department of Pediatrics, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorInmaculada Castillo, Inmaculada Castillo Department of Gastroenterology, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorMaria Dolores García-Novo, Maria Dolores García-Novo Department of Gastroenterology, Hospital Niño Jesús, 28009 Madrid, SpainSearch for more papers by this authorMaravillas Santos, Maravillas Santos Department of Pediatrics, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorSonia Navas, Sonia Navas Department of Gastroenterology, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridSearch for more papers by this authorDr. Vicente Carreño, Corresponding Author Dr. Vicente Carreño Department of Gastroenterology, Fundación Jiménez Diaz, Universidad Autónoma, 28040 MadridHepatology Unit, Department of Gastroenterology, Fundación Jiménez Díaz, Avda. Reyes católicos 2, 28040 Madrid, Spain===Search for more papers by this author First published: October 1992 https://doi.org/10.1002/hep.1840160405Citations: 70AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Twelve children with chronic non-A, non-B hepatitis were entered in a pilot trial of recombinant interferon-α. Although all the children had hepatitis C virus RNA in serum, only five had antibodies against this virus. Children received 3 MU/m2 body surface area interferon-α 3 times/wk for 6 mo; they were followed for 24 mo, including the therapy period. One child was dropped from the study, so the results are from the 11 children who completed the study. At the end of the therapy period, 36% of the children had normal ALT levels; this percentage increased to 90% at mo 15 of follow-up. Thereafter, relapse occurred in five children; thus ALT normalization was observed in 5 of 11 children at the 24th month. Moreover, two different ALT patterns were found: HCV antibody—negative children had significant peaks of ALT levels with respect to the basal samples (p < 0.05) until the third month of the therapy; these levels later decreased. In contrast, HCV antibody—positive children had slight fluctuations of ALT until normal levels were reached. At the end of treatment, three children had HCV RNA; one demonstrated a rebound in ALT levels. Finally, histological activity had decreased significantly in the second liver biopsy specimen in all children. In summary, interferon treatment in children with chronic hepatitis C may be helpful, although these results should be confirmed in controlled trials. (HEPATOLOGY 1992;16:882–885.) References 1 Houghton M, Weiner A, Han J, Kuo G, Choo Q-L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. HEPATOLOGY 1991; 14: 381– 388. 2 Kuo G, Choo Q-L, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 24: 362– 374. 3 Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas HC. Randomised controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. BMJ 1989; 298: 80– 82. 4 Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo controlled trial. N Engl J Med 1989; 321: 1506– 1510. 5 Davis GL, Balart LA, Schiff E, Lindsay K, Bodenheimer MC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 1989; 321: 1501– 1506. 6 Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreño V. High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C: A randomized, controlled trial. HEPATOLOGY 1991; 13: 327– 331. 7 Ruiz-Moreno M, Rua MJ, Molina J, Moraleda G, Moreno A, García-Aguado J, Carreño V. Prospective, randomized controlled trial of interferon α in children with chronic hepatitis B. HEPATOLOGY 1991; 13: 1035– 1039. 8 Houghton M, Choo Q-L, Kuo G. European Patent Application 90,302,866; Publication 388.232. 9 Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kierman TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981; 1: 431– 435. 10 Ruiz-Moreno M, Jimenez J, Porres JC, Bartolomé J, Moreno A, Carreño V. A controlled trial of recombinant interferon alpha in caucasian children with chronic hepatitis B. Digestion 1990; 45: 26– 33. 11 Shindo M, Di Bisceglie AM, Cheung L, Wai-Kuo J, Cristiano K, Feinstone SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700– 704. 12 Willems B, Villeneuve JP, Feiman SV, Vincelette J, Pomier-Lavrarques G. Autoantibodies anti-LKM and AMA during interferon treatment of chronic hepatitis C. [Abstract]. J Hepatol 1991; 13: S80. Citing Literature Volume16, Issue4October 1992Pages 882-885 ReferencesRelatedInformation